Canada is a recognized anchor donor of the Vaccine Alliance- leading global efforts to advance gender equality and women’s empowerment and reduce the burden of infectious diseases through vaccination. Gavi’s immunisation strategy was further supported by Canada’s 2018 G7 Presidency priorities: immunisation impacts on girls and boys, families, and economies. This approach is foundational to equitable growth and jobs, mitigating the health impacts of climate change, and building resilient systems and vaccine stockpiles to both prevent and respond to global health security threats.
Since 2002 Canada has invested over CAD 1 billion through Gavi and is a founding donor of the Pneumococcal Advance Market Commitment (AMC). Between 2002 and 2010 Canada contributed USD 277 million to Gavi including USD 152 million (CAD 188 million) in direct contributions and USD 125 million through the AMC. Canada’s total commitment to the AMC is USD 200 million.
In 2011, as part of Gavi’s first Replenishment, Canada pledged CAD 65 million in direct contributions to Gavi for 2011-2015. In 2013, Canada confirmed a direct grant of CAD 20 million for Gavi’s Measles Supplementary Immunisation Activities (MSIA) programme. In 2014, Canada contributed two additional CAD 20 million grants, respectively to support the Vaccine Alliance’s Immunisation Supply Chain Strategy and francophone countries’ immunisation activities – these contributions were made in line with the Muskoka Initiative.
In the lead-up to Gavi’s second Replenishment, Canada pledged CAD 500 million to Gavi to support immunization in development countries for the period 2016-2020, more than doubling the nation’s previous total contributions. Building upon this commitment a further CAD 20 million was pledged in January 2015 and has been allocated to Gavi’s innovation accelerator, INFUSE, for Francophone Africa. This commitment makes Canada the leading donor to INFUSE- underscoring the administration’s leadership in innovation.
On May 2020, in the lead to the Global Vaccine Summit, Canada pledged CAD 600 million to support Gavi’s efforts to deliver life-saving vaccines to children in the world’s poorest countries. This support arrived as the COVID-19 pandemic disrupted immunisation services in the poorest countries across the world. Canada’s commitment and global response to the pandemic was further accentuated through their CAD 220 million pledge to Gavi’s COVAX AMC to develop and deploy equitable distribution of effective and safe vaccines to middle- and lower-income countries.
Canadian leadership in immunisation extends beyond Gavi and includes contributions to the Canadian International Immunisation Initiative (C-III) between 1998 and 2013 and, as a top-five donor to the Global Polio Eradication Initiative (GPEI) since 1988.
Note: Proceeds are funds made available to Gavi from donor contributions and commitments, either through cash payments made to Gavi, through frontloading via the capital markets of a future donor commitment to IFFIm, or through AMC funds released to Gavi via the World Bank. IFFIm proceeds are allocated over five-year periods coinciding with Gavi’s strategic periods. Proceeds for the current and future strategic periods are indicative until the end of each period and could be revised following changes in market conditions (interest rates or foreign exchange rates), the signing of new pledge(s) and/or changes in IFFIm’s disbursement profile.
Click on Direct, IFFIm, AMC or Matching Fund in the above key to toggle their data on the graph, click again to show the data
Direct Contributions (including Matching Fund)
Received contributions: non-US$ contributions for 2000-2020 and Q1 2021 are expressed in US$ equivalents using the exchange rates on the dates of receipt. For 2014-2020 and Q1 2021 where contributions were hedged to mitigate currency risk exposure, these have been expressed using the rates applicable to the hedge agreement.
Future contributions (for pledges made prior to the June 2020 donor pledging conference): non-US$ Direct Contribution and Matching Fund pledges for Q2-Q4 2021 and years 2021 and beyond are expressed in US$ equivalents using the applicable forecast rates from Bloomberg as at 31 March 2021 or using the rates applicable to any hedge agreement in place.
Future contributions (for pledges at the June 2020 donor pledging conference): non-US$ Direct Contribution and Matching Fund pledges for Q2-Q4 2021 and for years 2021 and beyond are expressed in US$ equivalents using the spot rates from Bloomberg as at 31 March 2021 or using the rates applicable to any hedge agreement in place.
Received contributions: non-US$ contributions for 2000-2020 and for Q1 2021 are expressed in US$ equivalents as confirmed by the IBRD (World Bank)
'Future contributions: non-US$ contributions for Q2-Q4 2021 and for years 2021 and beyond are expressed in US$ equivalents as follows:
For signed contribution agreements: contributions are expressed in US$ equivalents using the exchange rates at the time of signing the respective donor grant agreements.
For contribution agreements not yet signed: contributions are expressed in US$ equivalents using the applicable spot rates from Bloomberg as at 31 March 2021.
Due to IFFIm’s nature as a frontloading vehicle, yearly contributions paid into IFFIm can differ significantly from yearly proceeds transferred to Gavi.
While IFFIm grants are irrevocable and legally binding, they are subject to a Grant Payment Condition that can potentially reduce the amount due by the donor in the event that a Gavi-supported programme country is in protracted arrears with the International Monetary Fund. IFFIm donor grant payments made during Q1 2021 were accordingly reduced by 0.5%, reflecting the number of these countries in arrears during that time. However, as the number of these countries in protracted arrears with the IMF can evolve, Gavi is not taking any assumption on future grant reduction value and reports future grants payable in full as indicated in the respective grant agreements.